Skip to main content

Leukemia, lymphoma, and myeloma.

83 Phase 1 studies recruiting right now, most recently updated first.

Open the Phase 2 page · a list of only those studies

Triangle is made by Triangle Health, Inc.

Leukemia, lymphoma, and myeloma83 studies

Advanced Myeloproliferative Neoplasms, MDS/MPN and High-Risk CMMLPhase 1/2NCT06523556

Axatilimab ± Azacitidine

Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia

Uma BorateOpen the brief

NeoplasmsPhase 1NCT05836896Papers

MDC-CAR-BCMA001 (BCMA directed CAR T-cells)

Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies

Technische Universität DresdenOpen the brief

Relapsed or Refractory Aggressive B-Cell LymphomaPhase 1/2NCT06536049

Epcoritamab + Ibrutinib

Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Yazeed SawalhaOpen the brief

T-cell Acute Lymphoblastic LymphomaPhase 1NCT03081910Papers

Autologous CD5.CAR/28zeta CAR T cells

Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen

Baylor College of MedicineOpen the brief

B-Cell LymphomaPhase 1/2NCT05092451Papers

CAR.70/IL15-transduced CB-NK cells

CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

M.D. Anderson Cancer CenterOpen the brief

Recurrent Childhood Acute Myeloid LeukemiaPhase 1NCT06609928Papers

FOLR1 CAR T-cells

FH-FOLR1 Chimeric Antigen Receptor T Cell Therapy for Treating Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia

Fred Hutchinson Cancer CenterOpen the brief

Recurrent Cutaneous T-Cell Non-Hodgkin LymphomaPhase 1/2NCT03011814Papers

Durvalumab

Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma

City of Hope Medical CenterOpen the brief

B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1Phase 1/2NCT01371630Papers

Inotuzumab Ozogamicin

Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia

M.D. Anderson Cancer CenterOpen the brief

Newly Diagnosed Acute Myeloid LeukemiaPhase 1NCT04659616Papers

Pemigatinib After Chemotherapy

Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia

OHSU Knight Cancer InstituteOpen the brief

Non-Hodgkin LymphomaPhase 1NCT05098613Papers

CD19x22 CAR T Cells

Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients

University of Colorado, DenverOpen the brief

Multiple MyelomaPhase 1NCT06185751

WS-CART-CS1

CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma

Washington University School of MedicineOpen the brief

C-Myc Rearranged High-Grade B-Cell Lymphoma or DLBCLPhase 1/2NCT06249191

Mosunetuzumab + Chemotherapy

Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma

OHSU Knight Cancer InstituteOpen the brief

AML or MDS Undergoing Reduced-Intensity TransplantPhase 1NCT06996119

Emapalumab for GVHD Prevention After Transplant

Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant

City of Hope Medical CenterOpen the brief

Acute Lymphoblastic LeukemiaPhase 1/2NCT03128034Papers

Cyclosporine

211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia

Fred Hutchinson Cancer CenterOpen the brief

Acute Myeloid LeukemiaPhase 1NCT04024761Papers

CIML NK

CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation

Dana-Farber Cancer InstituteOpen the brief

Clinical trials: Phase 1 and Phase 2, explained